No Detail Found!

SNP of HMGCR and Apo E genes and their impact in response to statin therapy in hypercholesterolemic and hypertriglyceridemic patients in Pakistan

Author(s)
Muhammad Rizwan Department of Biochemistry, Government College University,Faisalabad,Pakistan
Nosheen Aslam Department of Biochemistry, Government College University,Faisalabad,Pakistan
Usman Ali Ashfaq Department of Bioinformatics and Biotechnology, Government College University,Faisalabad,Pakistan
Muhammad Hayat Department of Biochemistry, Government College University,Faisalabad,Pakistan
Syed Makhdoom Hussain Fish Nutrition Lab., Department of Zoology, Government College University,Faisalabad,Pakistan
Abstract
Coronary artery disease (CAD) and the problems associated with it are the most prominent causes of death in the whole world. Statins are accustomed to lower lipid levels in CAD patients. The target of this study was to analyze whether or not common variations in HMGCoA Reductase (HMGCR) and Apolipoprotein E (ApoE) genes are responsible for metabolism of lipid and statin that modify the impact of statins on serum level of lipids and lipoprotein concentrations in Coronary heart disease patients. One hundred CAD patients were registered for the study. At the start of the study biochemical measurements were performed to work out the baseline levels. Patients were treated with twenty mg Lipitor for one month and biochemical measurements were tested again. According to the post-treatment, LDL-c levels, patients were divided into a pair of group as non-responders and responders, independently. The information concerning the risk factors like smoking, alcohol consumption etc. was conjointly obtained. DNA was extracted from peripheral blood. The presence of rs17244841 and rs17238540 mutations in HMGCR and e2, e3 and e4 variants of ApoE were settled by performing RT-PCR. Results were assessed statistically. HMGCR mutations were principally found in responders and e4 variant of ApoE was principally found in non-responders. It was found that the presence of HMGCR mutations causes a big reduction in total cholesterol and LDL-c levels. Conjointly, the presence of e2 variant of Apo E causes a statistically vital increase in triglyceride levels. Our findings should be investigated by different researchers to clarify the mechanism.
Publication Details
Page(s) 1577-1583
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP4, Year: 2021

Request the full text from PASTIC

Keywords
Single nucleotide polymorphism, low density lipoproteins, fibrate, Cholesterol, Statin
References
Abifadel M,Varret M,Rabes JP,Allard D,Ouguerram K,Devillers M,Boileau C M .2003 .Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet, 34(2) : 154-156.
Celermajer DS,Chow CK,Marijon E,Anstey NM,Woo KS .2012 .Cardiovascular disease in the developing world: Prevalences, patterns and the potential of early disease detection. J. Am. Coll. Cardiol, 60(14) : 1207-1216.
Chasman DI,Pare G,Mora S,Hopewell JC,Peloso G,Clarke R,Ridker PM .2009 .Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet, 5(11) : e1000730.
Chasman DI,Posada D,Subrahmanyan L,Cook NR,Ridker PM .2004 .Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA., 291(23) : 2821-2827.
Christidis DS,Liberopoulos EN,Kakafika AI,Miltiadous GA,Cariolou M,Ganotakis ES,Elisaf MS .2006 .The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. JCPT, 11(3) : 211-221.
Deo RC,Reich D,Tandon A,Akylbekova E,Patterson N,Waliszewska A,Wilson JG .2009 .Genetic differences between the determinants of lipid profile phenotypes in African and European Americans: The Jackson Heart Study. PLoS Genet, 5(1) : e1000342.
Deshmukh HA,Colhoun HM,Johnson T,McKeigue PM,Betteridge DJ,Durrington PN,Hitman GA .2012 .Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp (a). J. Lipid Res., 53(5) : 1000-1011.
Fiegenbaum M,da Silveira FR,Van der Sand CR,Van der Sand LC,Ferreira ME,Pires RC,Hutz MH .2005 .Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta., 362(1-2) : 182-188.
Ilveskoski E,Loimaala A,Mercuri MF,Lehtimäki T,Pasanen M,Nenonen A,Vuori I .2000 .Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample of middleaged men. Atherosclerosis, 153(1) : 147-153.
Inouye M,Ripatti S,Kettunen J,Lyytikainen LP,Oksala N,Laurila PP,De Bakker PI PP .2012 .Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet, 8(8) : e1002907.
Kathiresan S,Melander O,Guiducci C,Surti A,Burtt NP,Rieder MJ,Orho-Melander M .2008 .Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet, 40(2) : 189-197.
Kim YJ,Go MJ,Hu C,Hong CB,Kim YK,Lee JY,Cho YS .2011 .Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. Nat. Genet, 43(10) : 990.
Kooner JS,Chambers JC,Aguilar-Salinas CA,Hinds DA,Hyde CL,Warnes GR,Thompson JF GR .2008 .Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet, 40(2) : 149.
Krauss RM,Mangravite LM,Smith JD,Medina MW,Wang D,Guo X,Rotter JI .2008 .Clinical perspective. Circulation, 117(12) : 1537-1544.
Lehtimäki T,Moilanen T,Nikkari T,Solakivi T,Porkka K,Ehnholm C,Viikari J .1991 .Regional differences in apolipoprotein E polymorphism in Finland. , 23(1) : 61-66.
Liberopoulos E,Siamopoulos K,Elisaf M K .2004 .Apolipoprotein E and renal disease. AJKD, 43(2) : 223-233.
Luc G,Bard JM,Arveiler D,Evans A,Cambou JP,Bingham A,Cambien F A .1994 .Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler. Thromb. Vasc. Biol, 14(9) : 1412-1419.
Mahley RW .1988 .Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science, 240(4852) : 622-630.
Mangravite LM,Krauss RM .2007 .Pharmacogenomics of statin response. Curr. Opin. Lipidol., 18(4) : 409-414.
Mangravite LM,Thorn CF,Krauss RM .2006 .Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics, 6(6) : 360-374.
Neiminen T,Kahonen M,Viiri LE,Gronroos P,Lehtimaki T .2008 .Pharmacogenetics of apoliproprotein E gene during lipid-lowering therapy: Lipid levels and prevention of coronary heart disease. Pharmacogenomics, 9(10) : 1475-1486.
Pena R,Lahoz C,Mostaza JM,Jimenez J,Subirats E,Pinto X .2002 .Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med, 251(6) : 518-525.
Peters BJ,Pett H,Klungel OH,Stricker BHC,Psaty BM,Glazer NL,Maitland-van der Zee AH .2011 .Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. , 217(2) : 458-464.
Poduri A,Khullar M,Bahl A,Sehrawat BS,Sharma Y,Talwar KK Y .2010 .Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4 and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol, 29(10) : 629-637.
Polisecki E,Muallem H,Maeda N,Peter I,Robertson M,McMahon AD .2008 .Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. , 200(1) : 109-114.
Postmus I,Verschuren JJ,De Craen AJ,Slagboom PE,Westendorp RG,Jukema JW,Trompet S JW .2012 .Pharmacogenetics of statins: Achievements, wholegenome analyses and future perspectives. Pharmacogenomics, 13(7) : 831-840.
Radovica I,Fridmanis D,Silamikelis I,Nikitina-Zake L,Klovins J .2014 .Association between CETP, MLXIPL and TOMM40 polymorphisms and serum lipid levels in a Latvian population. Meta Gene, 2 : 565-578.
Saidi S,Slamia LB,Ammou SB,Mahjoub T,Almawi WY .2007 .Association of apolipoprotein E gene polymorphism with ischemic stroke involving largevessel disease and its relation to serum lipid levels. J. Stroke Cerebrovasc. Dis., 16(4) : 160-166.
Sanllehy C,Casals E,Rodriguez-Villar C,Zambón D,Ojuel J,Ballesta AM,Ros E .1998 .Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism, 47(5) : 560-565.
.2009 .HardyWeinberg equilibrium calculator including analysis for ascertainment bias. Am. J. Epidemiol. Advance Access, 169(4) : 505-514.
Sarzynski MA,Jacobson P,Rankinen T,Carlsson B,Sjöström L,Carlsson LM,Bouchard C .2011 .Association of GWAS-based candidate genes with HDL-cholesterol levels before and after bariatric surgery in the Swedish obese subjects study. J. Clin. Endocrinol. Metab., 96(6) : E953-E957.
Langmann Schmitz G,T Schmitz G .2006 .Pharmacogenomics of cholesterol-lowering therapy. Curr. Vasc. Pharmacol., 44(2) : 75-89.
Shanmugasundaram M,Rough SJ,Alpert JS .2010 .Dyslipidemia in the elderly: Should it be treated? Clin. , 33(1) : 4-9.
Teslovich TM,Musunuru K,Smith AV,Edmondson AC,Stylianou IM,Koseki M,Dominiczak AF M .2010 .Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 466(7307) : 707-713.
Thompson JF,Hyde CL,Wood LS,Paciga SA,Hinds DA,Cox DR,Kastelein JJ .2009 .Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ. Cardiovasc. Genet, 2(2) : 173-181.
Thompson JF,Man M,Johnson KJ,Wood LS,Lira ME,Lloyd DB,Sasiela WJ .2005 .An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J., 5(6) : 352-358.
Utermann G .1987 .Apolipoprotein E polymorphism in health and disease. Am. Heart J., 113(2) : 433-440.
Voora D,Shah SH,Reed CR,Zhai J,Crosslin DR,Messer C,Ginsburg GS C .2008 .Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet, 1(2) : 100-106.
Wallace C,Newhouse SJ,Braund P,Zhang F,Tobin M,Falchi M,Wellcome Trust Case Control Consortium M .2008 .Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet, 82(1) : 139-149.
Willer CJ,Sanna S,Jackson AU,Scuteri A,Bonnycastle LL,Clarke R,Abecasis GR .2008 .Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet, 40(2) : 161-169.
Yamauchi K,Tozuka M,Nakabayashi T,Sugano M,Hidaka H,Kondo Y,Katsuyama T Y .1999 .Apolipoprotein E in cerebrospinal fluid: Relation to phenotype and plasma apolipoprotein E concentrations. Clin. Chem, 45(4) : 497-504.
Zintzaras E,Kitsios GD,Triposkiadis F,Lau J,Raman G .2009 .APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J., 9(4) : 248-257.
0

Citations

0

Downloads

13

Views